FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966912437> ?p ?o ?g. }

• W1966912437 endingPage "2108" @default.
• W1966912437 startingPage "2108" @default.
• W1966912437 abstract "<h3>Context</h3>Heart failure with preserved ejection fraction (HFPEF) may be as common and as lethal as heart failure with reduced ejection fraction (HFREF). Three randomized trials of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ie, renin-angiotensin system [RAS] antagonists) did not reach primary end points but may have had selection bias or been underpowered.<h3>Objective</h3>To test the hypothesis that use of RAS antagonists is associated with reduced all-cause mortality in an unselected population with HFPEF.<h3>Design, Setting, and Patients</h3>Prospective study using the Swedish Heart Failure Registry of 41 791 unique patients registered from 64 hospitals and 84 outpatient clinics between 2000 and 2011. Of these, 16 216 patients with HFPEF (ejection fraction ≥40%; mean [SD] age, 75 [11] years; 46% women) were either treated (n = 12 543) or not treated (n = 3673) with RAS antagonists. Propensity scores for RAS antagonist use were derived from 43 variables. The association between use of RAS antagonists and all-cause mortality was assessed in a cohort matched 1:1 based on age and propensity score and in the overall cohort with adjustment for propensity score as a continuous covariate. To assess consistency, separate age and propensity score–matched analyses were performed according to RAS antagonist dose in patients with HFPEF and in 20 111 patients with HFREF (ejection fraction <40%) in the same registry.<h3>Main Outcome Measure</h3>All-cause mortality.<h3>Results</h3>In the matched HFPEF cohort, 1-year survival was 77% (95% CI, 75%-78%) for treated patients vs 72% (95% CI, 70%-73%) for untreated patients, with a hazard ratio (HR) of 0.91 (95% CI, 0.85-0.98; P = .008). In the overall HFPEF cohort, crude 1-year survival was 86% (95% CI, 86%-87%) for treated patients vs 69% (95% CI, 68%-71%) for untreated patients, with a propensity score–adjusted HR of 0.90 (95% CI, 0.85-0.96; P = .001). In the HFPEF dose analysis, the HR was 0.85 (95% CI, 0.78-0.83) for 50% or greater of target dose vs no treatment (P < .001) and 0.94 (95% CI, 0.87-1.02) for less than 50% of target dose vs no treatment (P = .14). In the age and propensity score–matched HFREF analysis, the HR was 0.80 (95% CI, 0.74-0.86; P < .001).<h3>Conclusion</h3>Among patients with heart failure and preserved ejection fraction, the use of RAS antagonists was associated with lower all-cause mortality." @default.
• W1966912437 created "2016-06-24" @default.
• W1966912437 creator A5042030729 @default.
• W1966912437 creator A5067972379 @default.
• W1966912437 creator A5078434356 @default.
• W1966912437 creator A5078817987 @default.
• W1966912437 date "2012-11-28" @default.
• W1966912437 modified "2023-10-18" @default.
• W1966912437 title "Association Between Use of Renin-Angiotensin System Antagonists and Mortality in Patients With Heart Failure and Preserved Ejection Fraction" @default.
• W1966912437 cites W118062040 @default.
• W1966912437 cites W1519753475 @default.
• W1966912437 cites W180946569 @default.
• W1966912437 cites W1961002235 @default.
• W1966912437 cites W1965000519 @default.
• W1966912437 cites W1974689215 @default.
• W1966912437 cites W1989377468 @default.
• W1966912437 cites W2011058300 @default.
• W1966912437 cites W2014799253 @default.
• W1966912437 cites W2028139057 @default.
• W1966912437 cites W2033989169 @default.
• W1966912437 cites W2043990618 @default.
• W1966912437 cites W2055123579 @default.
• W1966912437 cites W2057047340 @default.
• W1966912437 cites W2060516690 @default.
• W1966912437 cites W2060995105 @default.
• W1966912437 cites W2068519950 @default.
• W1966912437 cites W2079882571 @default.
• W1966912437 cites W2086291738 @default.
• W1966912437 cites W2093029369 @default.
• W1966912437 cites W2099949500 @default.
• W1966912437 cites W2100454833 @default.
• W1966912437 cites W2105138814 @default.
• W1966912437 cites W2109051856 @default.
• W1966912437 cites W2110285846 @default.
• W1966912437 cites W2114109157 @default.
• W1966912437 cites W2119061468 @default.
• W1966912437 cites W2121690051 @default.
• W1966912437 cites W2127254785 @default.
• W1966912437 cites W2129711762 @default.
• W1966912437 cites W2135038122 @default.
• W1966912437 cites W2137087688 @default.
• W1966912437 cites W2137784332 @default.
• W1966912437 cites W2148910374 @default.
• W1966912437 cites W2165842183 @default.
• W1966912437 cites W2170366996 @default.
• W1966912437 cites W2284554048 @default.
• W1966912437 cites W2305118939 @default.
• W1966912437 cites W3108630675 @default.
• W1966912437 cites W3122049309 @default.
• W1966912437 doi "https://doi.org/10.1001/jama.2012.14785" @default.
• W1966912437 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23188027" @default.
• W1966912437 hasPublicationYear "2012" @default.
• W1966912437 type Work @default.
• W1966912437 sameAs 1966912437 @default.
• W1966912437 citedByCount "146" @default.
• W1966912437 countsByYear W19669124372012 @default.
• W1966912437 countsByYear W19669124372013 @default.
• W1966912437 countsByYear W19669124372014 @default.
• W1966912437 countsByYear W19669124372015 @default.
• W1966912437 countsByYear W19669124372016 @default.
• W1966912437 countsByYear W19669124372017 @default.
• W1966912437 countsByYear W19669124372018 @default.
• W1966912437 countsByYear W19669124372019 @default.
• W1966912437 countsByYear W19669124372020 @default.
• W1966912437 countsByYear W19669124372021 @default.
• W1966912437 countsByYear W19669124372022 @default.
• W1966912437 countsByYear W19669124372023 @default.
• W1966912437 crossrefType "journal-article" @default.
• W1966912437 hasAuthorship W1966912437A5042030729 @default.
• W1966912437 hasAuthorship W1966912437A5067972379 @default.
• W1966912437 hasAuthorship W1966912437A5078434356 @default.
• W1966912437 hasAuthorship W1966912437A5078817987 @default.
• W1966912437 hasBestOaLocation W19669124371 @default.
• W1966912437 hasConcept C126322002 @default.
• W1966912437 hasConcept C164705383 @default.
• W1966912437 hasConcept C17923572 @default.
• W1966912437 hasConcept C2777099384 @default.
• W1966912437 hasConcept C2778198053 @default.
• W1966912437 hasConcept C71924100 @default.
• W1966912437 hasConcept C72563966 @default.
• W1966912437 hasConcept C78085059 @default.
• W1966912437 hasConceptScore W1966912437C126322002 @default.
• W1966912437 hasConceptScore W1966912437C164705383 @default.
• W1966912437 hasConceptScore W1966912437C17923572 @default.
• W1966912437 hasConceptScore W1966912437C2777099384 @default.
• W1966912437 hasConceptScore W1966912437C2778198053 @default.
• W1966912437 hasConceptScore W1966912437C71924100 @default.
• W1966912437 hasConceptScore W1966912437C72563966 @default.
• W1966912437 hasConceptScore W1966912437C78085059 @default.
• W1966912437 hasIssue "20" @default.
• W1966912437 hasLocation W19669124371 @default.
• W1966912437 hasLocation W19669124372 @default.
• W1966912437 hasOpenAccess W1966912437 @default.
• W1966912437 hasPrimaryLocation W19669124371 @default.
• W1966912437 hasRelatedWork W1964205598 @default.
• W1966912437 hasRelatedWork W2051712573 @default.
• W1966912437 hasRelatedWork W2061321770 @default.
• W1966912437 hasRelatedWork W2077083067 @default.

• next